Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Resistant hypertension is defined as hypertension uncontrolled with optimal doses of three antihypertensive agents, one of which is a diuretic. The up-to-date approaches to optimal pharmacologic and interventional treatment are discussed. Special emphasis is placed on some controversial aspects of new interventional procedures for resistant hypertension correction.

About the Authors

Yu. I. Grinshtein
Krasnoyarsk State Medical University named after Prof. V.F. Voyno-Yasenetsky
Russian Federation
Partizana Zheleznyaka ul. 1, Krasnoyarsk, 660022 Russia

V. V. Shabalin
Krasnoyarsk State Medical University named after Prof. V.F. Voyno-Yasenetsky
Russian Federation
Partizana Zheleznyaka ul. 1, Krasnoyarsk, 660022 Russia


1. CalhounD.A., JonesD., Textor S. et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.Circulation 2008;117(25):e510-26.

2. Judd E., Calhone D.A. Apparent and true resistant hypertension: definition, prevalence and outcomes. J Hum Hypertens 2014;28(8):463-8.

3. Hermida R.C., Ayala D.E., Mojon A. et al. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int 2010;27(8):1629-51.

4. Kleman M., Dhaniamraji S., Difillippo W. Prevalance and characteristics of pseudohypertension in patients with “resistant hypertension”. J Am Soc Hypertens 2013;7(6):467-70.

5. Mancia G., Fagard R., Narkieicz K. et al. 2013 practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens 2013;31(10):1925-38.

6. Paiva L., Cachulo M.C., Providencia R. et al. Overview of resistant hypertension: a glimpse of the cardiologist’s current standpoint. World J Cardiol 2012;4(9):275-83.

7. Phillips C.L., O’Driscoll D.M. Hypertension and obstructive sleep apnea. Nat Sci Sleep 2013;5:43-52.

8. Gaddam K., Pimenta E., Thomas S.J. et al. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens 2010;24(8):532-8.

9. Mann S.J., Sos T.A. The cardiovascular outcomes in renal atherosclerotic lesions study and the future of renal artery stenting. J Clin Hypertens (Greenwich) 2014;6(3):162-5.

10. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011;32(22):2851-906.

11. Cooper C.J., Murphy T.P., Cutlip D.E. et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 2014;370(1):13-22.

12. Leesar M.A., Varma J., Shapira A. et al. Prediction of hypertension improvement after stenting of renal artery stenosis: comparative accuracy of translesional pressure gradients, intravascular ultrasound, and angiography. J Am Coll Cardiol 2009;53(25):2363-71.

13. Hanselin M.R., Saseen J.J., Allen R.R. et al. Description of antihypertensive use in patients with resistant hypertension prescribed four or more agents. Hypertension 2011;58(6):1008-13.

14. National Institute for Health and Clinical Excellence. Hypertension (CG127): clinical management of primary hypertension in adults. Published date: August 2011. Accessed by: 19.10.2014.

15. Weber M.A., Schiffrin E.L., White W.B. et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American society of hypertension and the international society of hypertension. J Hypertens 2014;32(1):3-15.

16. Kumar N., Calhoun D.A., Dudenbostel T. Management of patients with resistant hypertension: current treatment options. Integr Blood Press Control 2013;22(6):139-51.

17. Guichard J.L., Clark D. 3rd, Calhoun D.A. et al. Aldosterone receptor antagonists: current perspectives and therapies. Vasc Health Risk Manag 2013;9:321-31.

18. Hansen T.W., Li Y., Boggia J. et al. Predictive role of the nighttime blood pressure. Hypertension 2011;57(1):3-10.

19. Almirall J., Comas L., Martinez-Ocana J.C. et al. Effects of chronotherapy on blood pressure control in non-dipper patients with refractory hypertension. Nephrol Dial Nransplant 2012;27(5):1855-59.

20. Zhao P., Xu P., Wan C. et al. Evening versus morning dosing regimen drug therapy for hypertension. Cochrane Database Syst Rev 2011;10: CD004184.

21. Hermida R.C., Ayala D.E., Smolensky M.H. et al. Chronotherapeutics of conventional blood pressurelowering medications: simple, low-cost means of improving management and treatment outcomes of hypertensive-related disorders. Curr Hypertens Rep 2014;16(2):412.

22. Turgeon R., Allan G.M. Taking blood pressure-lowering medications at night. Can Fam Physician 2012;58(9):965.

23. Standards of medical care in diabetes – 2013. Diabetes Care 2013;36(Suppl 1):S11-66.

24. Rahman M., Greene T., Phillips R.F. et al. A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease. Hypertension 2013;61(1):82-8.

25. Crespo J.J., Pineiro L., Otero A. et al. Administration-time-dependent effects of hypertension treatment on ambulatory blood pressure in patients with chronic kidney disease. Chronobiol Int 2013;30(1-2):159-75.

26. Urban D., Ewen S., Ukena C. et al. Treating resistant hypertension: role of renal denervation. Integr Blood Press Control 2013;6:119-28.

27. Krum H., Schlaich M., Whitbourn R. et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009;373(9671):1275-81.

28. Krum H., Schlaich M.P., Sobotka PA. et al. Percutaneous renal denervation in patients with treatmentresistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet 2014;383(9917):622-29.

29. Symplicity HTN-2 Investigators, Esler M.D., Krum H., Sobotka P.A. et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomized controlled trial. Lancet 2010;376(9756):1903-09.

30. Esler M.D, Bohm M., Sievert H. et al.Catheter-based renal denervation for the treatment of patients for the treatment of patients with treatment-resistant hypertension: 36 month results from the SIMPLICITYHTN-2 randomized clinical trial. Eur Heart J 2014; 35(26):1752-59.

31. Bhatt D.L., Kandzari D.E., O’Neill W.W. et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014;370(15):1393-401.

32. Davis M.I., Filion K.B., Zhang D. et al. Effectiveness of renal denervation therapy for resistant hypertension: a systematic review and meta-analysis. J Am Coll Cardiol 2013;62(3):231-41.

33. Mahfoud F., Luscher T.F., Andersson B. et al. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J 2013;34(28):2149-57.

34. Schlaich M.P., Schmieder R.E., Bakris G. et al. International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol 2013;62(22):2031-45.

35. Tsioufis C., Mahfould F., Mancia G. et al. What the interventionalist should know about renal denervation in hypertensive patients: a position paper by the ESH WG on the interventional treatment of hypertension. Euro Intervention 2014;9(9):1027-35.

36. Hering D., Esler M.D., Schlaich M.P. et al. Chronic kidney disease: role of sympathetic nervous system activation and potential benefits of renal denervation. Euro Intervention 2013;9 Suppl R:R127-35.

37. Ziegler A.K., Franke J., Bertog S.C. Renal denervation in a patient with prior renal artery stenting. Catheter Cardiovasc Interv 2013;81(2):342-45.

38. Schlaich M.P., Esler M.D., Fink G.D. et al. Targeting the sympathetic nervous system: critical issues in patient selection, efficacy, and safety of renal denervation. Hypertension 2014;63(3):426-32.

39. Pathak A., Ewen S., Fajadet J. et al. From Symlicity HTN-3 to the Renal Denervation Global Registry: where do we stand and where should we go? Euro Intervention 2014;10(1):21-3.

40. BohmM., MahfoudF., UkenaC.etal. Rationale and design of a large registry on renal denervation: the Global SYMPLICITY registry. Euro Intervention 2013;9(4):484-92.

41. Ariyanon W., Mao H., Adybelli Z. et al. Renal denervation: intractable hypertension and beyond. Cardio Renal Med 2014;4(1):22-3.

42. Mendelsohn F.O. Does complete renal denervation translate into superior clinical outcomes? Lessons learned from denervation of accessory renal arteries. Clin Res Cardiol 2014;103(9):681-3.

43. Ott C., Mahfoud F., Schmid A. et al. Improvement of albuminuria after renal denervation. Int J Cardiol 2014;173(2):311-5.

44. Mahfoud F., Urban D., Teller D. et al. Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial. Eur Heart J 2014;35(33):2224-31.

For citation:


Views: 581

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)